Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.63
PODD's Cash to Debt is ranked lower than
65% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. PODD: 0.63 )
Ranked among companies with meaningful Cash to Debt only.
PODD' s Cash to Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.12 Max: N/A
Current: 0.63
Equity to Asset 0.10
PODD's Equity to Asset is ranked lower than
94% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. PODD: 0.10 )
Ranked among companies with meaningful Equity to Asset only.
PODD' s Equity to Asset Range Over the Past 10 Years
Min: -2.37  Med: 0.27 Max: 0.73
Current: 0.1
-2.37
0.73
F-Score: 2
Z-Score: 4.17
M-Score: -3.17
WACC vs ROIC
14.20%
-51.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -13.70
PODD's Operating margin (%) is ranked lower than
69% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. PODD: -13.70 )
Ranked among companies with meaningful Operating margin (%) only.
PODD' s Operating margin (%) Range Over the Past 10 Years
Min: -945.81  Med: -33.87 Max: -4.26
Current: -13.7
-945.81
-4.26
Net-margin (%) -17.68
PODD's Net-margin (%) is ranked lower than
69% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. PODD: -17.68 )
Ranked among companies with meaningful Net-margin (%) only.
PODD' s Net-margin (%) Range Over the Past 10 Years
Min: -981.44  Med: -46.59 Max: -17.68
Current: -17.68
-981.44
-17.68
ROE (%) -147.54
PODD's ROE (%) is ranked lower than
95% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.19 vs. PODD: -147.54 )
Ranked among companies with meaningful ROE (%) only.
PODD' s ROE (%) Range Over the Past 10 Years
Min: -178.71  Med: -92.23 Max: -49.42
Current: -147.54
-178.71
-49.42
ROA (%) -22.70
PODD's ROA (%) is ranked lower than
75% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. PODD: -22.70 )
Ranked among companies with meaningful ROA (%) only.
PODD' s ROA (%) Range Over the Past 10 Years
Min: -97.25  Med: -31.5 Max: -17.6
Current: -22.7
-97.25
-17.6
ROC (Joel Greenblatt) (%) -92.80
PODD's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.92 vs. PODD: -92.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PODD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -310.53  Med: -166.07 Max: -65.62
Current: -92.8
-310.53
-65.62
Revenue Growth (3Y)(%) 9.00
PODD's Revenue Growth (3Y)(%) is ranked higher than
69% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. PODD: 9.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PODD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 16.8 Max: 99.7
Current: 9
0
99.7
EBITDA Growth (3Y)(%) 15.10
PODD's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. PODD: 15.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PODD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -72.6  Med: -34 Max: 25.9
Current: 15.1
-72.6
25.9
EPS Growth (3Y)(%) 6.10
PODD's EPS Growth (3Y)(%) is ranked higher than
51% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. PODD: 6.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PODD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -71  Med: -21.7 Max: 31.2
Current: 6.1
-71
31.2
» PODD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

PODD Guru Trades in Q3 2015

Ken Fisher 16,963 sh (+76.92%)
PRIMECAP Management 5,194,669 sh (+3.22%)
Pioneer Investments 329,332 sh (-3.49%)
Steven Cohen 23,200 sh (-31.76%)
Mariko Gordon 1,323,195 sh (-35.71%)
» More
Q4 2015

PODD Guru Trades in Q4 2015

Jim Simons 81,600 sh (New)
Steven Cohen 196,400 sh (+746.55%)
PRIMECAP Management 5,195,669 sh (+0.02%)
Ken Fisher 16,963 sh (unchged)
Mariko Gordon 1,316,540 sh (-0.50%)
Pioneer Investments 287,180 sh (-12.80%)
» More
Q1 2016

PODD Guru Trades in Q1 2016

Jim Simons 222,400 sh (+172.55%)
Mariko Gordon 1,483,179 sh (+12.66%)
Ken Fisher 16,963 sh (unchged)
Steven Cohen Sold Out
PRIMECAP Management 5,194,369 sh (-0.03%)
Pioneer Investments 255,521 sh (-11.02%)
» More
Q2 2016

PODD Guru Trades in Q2 2016

Jim Simons 620,892 sh (+179.18%)
Ken Fisher 16,963 sh (unchged)
Mariko Gordon Sold Out
PRIMECAP Management 5,189,472 sh (-0.09%)
Pioneer Investments 32,665 sh (-87.22%)
» More
» Details

Insider Trades

Latest Guru Trades with PODD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:OTCPK:ANSLF, NAS:ICUI, NYSE:HAE, NYSE:CMN, NAS:NXTM, NYSE:HYH, OTCPK:TOPCF, NYSE:GKOS, NAS:MMSI, NYSE:HRC, NAS:ELGX, NAS:LMNX, OTCPK:NNCSF, NAS:NVCR, NAS:ATRI, OTCPK:KSRBF, NAS:ANGO, NAS:ATRC, NAS:OSUR, NAS:UNIS » details
Traded in other countries:GOV.Germany,
Insulet Corp is a medical device company that develops, manufactures and markets OmniPod Insulin Management System, an insulin infusion system for people with insulin-dependent diabetes.

Insulet Corp is a Delaware corporation formed in July 2000. The Company is engaged in the development, manufacturing and sale of OmniPod Insulin Management System. The OmniPod System is a disposable tubeless OmniPod worn on the body for approximately three days at a time. OmniPod Insulin Management System consists of disposable tubeless OmniPod worn on the body for approximatley three days at a time. The OmniPod System features two devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. In October 2005 the Company began its commercial sale of OmniPod System in the United States. The Company sells OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through distribution partners. The OmniPod System is available in Europe through distribution partner, Ypsomed Distribution AG and in Canada through the distribution partner GlaxoSmithKline. The Company's sales and marketing effort is focused on generating demand and acceptance of the OmniPod System among diabetes practitioners, academic medical centers, clinics, insulin-dependent diabetes patients, third-party payors, government agencies, and third-party distributors. The marketing strategy is to build awareness for the benefits of the OmniPod System through education programs, social networking, patient demonstration programs, support materials, media advertisements and events at the national, regional and local levels. As of December 31, 2013, the Company had obtained 15 issued United States patents, and had 8 additional pending U.S. patent applications. It has registered the trademarks OMNIPOD, INSULET and the OMNIPOD design with the United States Patent and Trademark Office on the Principal Register. The OmniPod System competes with Medtronic MiniMed, Animas Corporation, Tandem Diabetes Care, Inc. and Roche Diagnostics, a division of F. Hoffmann-La Roche, Ltd.

Ratios

vs
industry
vs
history
P/B 90.31
PODD's P/B is ranked lower than
100% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. PODD: 90.31 )
Ranked among companies with meaningful P/B only.
PODD' s P/B Range Over the Past 10 Years
Min: 3.13  Med: 15.25 Max: 1235
Current: 90.31
3.13
1235
P/S 6.93
PODD's P/S is ranked lower than
78% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. PODD: 6.93 )
Ranked among companies with meaningful P/S only.
PODD' s P/S Range Over the Past 10 Years
Min: 1.2  Med: 6.08 Max: 22.41
Current: 6.93
1.2
22.41
Current Ratio 3.29
PODD's Current Ratio is ranked higher than
66% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. PODD: 3.29 )
Ranked among companies with meaningful Current Ratio only.
PODD' s Current Ratio Range Over the Past 10 Years
Min: 0.67  Med: 4.68 Max: 8.04
Current: 3.29
0.67
8.04
Quick Ratio 2.84
PODD's Quick Ratio is ranked higher than
74% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. PODD: 2.84 )
Ranked among companies with meaningful Quick Ratio only.
PODD' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 4.29 Max: 7.56
Current: 2.84
0.56
7.56
Days Inventory 36.00
PODD's Days Inventory is ranked higher than
92% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.57 vs. PODD: 36.00 )
Ranked among companies with meaningful Days Inventory only.
PODD' s Days Inventory Range Over the Past 10 Years
Min: 28.13  Med: 49.61 Max: 111.63
Current: 36
28.13
111.63
Days Sales Outstanding 39.68
PODD's Days Sales Outstanding is ranked higher than
83% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.25 vs. PODD: 39.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
PODD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.68  Med: 60.44 Max: 141.2
Current: 39.68
39.68
141.2
Days Payable 43.69
PODD's Days Payable is ranked lower than
55% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 48.01 vs. PODD: 43.69 )
Ranked among companies with meaningful Days Payable only.
PODD' s Days Payable Range Over the Past 10 Years
Min: 28.7  Med: 46.8 Max: 80.41
Current: 43.69
28.7
80.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.60
PODD's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. PODD: -5.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PODD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -370.3  Med: -10.1 Max: -0.9
Current: -5.6
-370.3
-0.9

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.14
PODD's Price/Median PS Value is ranked higher than
53% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.18 vs. PODD: 1.14 )
Ranked among companies with meaningful Price/Median PS Value only.
PODD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 0.99 Max: 2.82
Current: 1.14
0.2
2.82
Earnings Yield (Greenblatt) (%) -1.93
PODD's Earnings Yield (Greenblatt) (%) is ranked lower than
63% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. PODD: -1.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PODD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -5.1  Med: 0 Max: 0
Current: -1.93
-5.1
0

More Statistics

Revenue (TTM) (Mil) $356.0
EPS (TTM) $ -1.11
Beta1.74
Short Percentage of Float9.75%
52-Week Range $23.94 - 45.60
Shares Outstanding (Mil)57.27

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 350 412 504
EPS ($) -0.55 -0.16 0.18
EPS w/o NRI ($) -0.55 -0.16 0.18
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for PODD

Headlines

Articles On GuruFocus.com
Mariko Gordon's Trades In Q1 2015 Jun 12 2015 
Weekly CEO Buys Highlight: NUVA, HK, BKFS, PODD, CLF Jun 02 2015 
Insulet Corp. (PODD) President and CEO Duane Desisto sells 24,400 Shares Feb 18 2011 
Insulet Corp. (PODD) President and CEO Duane Desisto sells 27,000 Shares Feb 15 2011 
Insulet Corp. Reports Operating Results (10-Q) Aug 09 2010 
Insulet Corp. Reports Operating Results (10-Q) Aug 09 2010 
Insulet Corp. Reports Operating Results (10-Q) May 07 2010 
Insulet Corp. (PODD) COO Luis Malave sells 6,000 Shares Dec 23 2009 
Insulet Corp. (PODD) COO Luis Malave sells 5,116 Shares Nov 24 2009 
Insulet Corp. (PODD) COO Luis Malave sells 6,000 Shares Nov 03 2009 

More From Other Websites
INSULET CORP Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an... Sep 13 2016
Insulet Enrolls First Patients in Clinical Trial for its Omnipod® Artificial Pancreas System Sep 13 2016
Insulet Enrolls First Patients in Clinical Trial for its Omnipod® Artificial Pancreas System Sep 13 2016
Insulet Announces Pricing of Convertible Senior Notes Due 2021 Sep 07 2016
Insulet Announces Pricing of Convertible Senior Notes Due 2021 Sep 07 2016
Insulet Announces Private Offering of Convertible Senior Notes Sep 06 2016
INSULET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 06 2016
Insulet Announces Private Offering of Convertible Senior Notes Sep 06 2016
Insulet Announces Executive Appointments Sep 06 2016
Insulet to Establish Highly-Automated Manufacturing Operation in the United States Sep 06 2016
Insulet to Establish Highly-Automated Manufacturing Operation in the United States Sep 06 2016
Insulet Announces Executive Appointments Sep 06 2016
INSULET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Sep 01 2016
ETF’s with exposure to Insulet Corp. : September 1, 2016 Sep 01 2016
Will Insulet (PODD) Crush Estimates at Its Next Earnings Report? Sep 01 2016
INSULET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification... Aug 31 2016
Moving Average Crossover Alert: Insulet (PODD) Aug 16 2016
Can The Uptrend Continue for Insulet (PODD)? Aug 15 2016
INSULET CORP Financials Aug 11 2016
ETF’s with exposure to Insulet Corp. : August 9, 2016 Aug 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)